Following the FDA approval of a pneumococcal 15-valent conjugate vaccine (Vaxneuvance) for the prevention of invasive disease caused by Streptococcus pneumoniae in children, we were delighted to speak with Dr. Steven Shapiro (Jefferson Abington Hospital, Abington, PA, USA) to discuss the unmet needs, the clinical data supporting the approval, and the impact approval will have on preventing invasive pneumococcal disease. […]

Asthma is a chronic heterogenous disease, airway eosinophilic inflammation can be reduced with biologics; however, there remains many unmet needs in the treatment of type-2 low severe asthma. It was a pleasure to talk with our editorial board member, Prof. Antonio Spanevello (University of Insubria and Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy) […]

Asthma is a chronic heterogenous disease, airway eosinophilic inflammation can be reduced with biologics; however, there remains many unmet needs in the treatment of type-2 low severe asthma. touchRESPIRATORY were delighted to catch up with editorial board member, Prof. Antonio Spanevello (University of Insubria and Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy) to […]

Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]

It was a pleasure to talk with Dr Ronald Strauss (Cleveland Allergy and Asthma Center; Case Western Reserve University Medical School, Cleveland, OH, USA) around his article exploring the use of intranasal corticosteroids in the prevention and/ or treatment of COVID-19. Questions What is known about the major ports of entry for the SARS-CoV-2 virus? […]

touchRESPIRATORY were delighted to talk with Dr Ronald Strauss (Cleveland Allergy and Asthma Center; Case Western Reserve University Medical School, Cleveland, OH, USA) around his analysis of the association of eosinophilia with improved COVID-19 outcomes in patients treated with inhaled corticosteroids. The abstract ‘Eosinophilia is Associated with Improved COVID-19 Outcomes in Patients Treated with Inhaled […]

We were delighted to talk with Dr. Sharmilee Nyenhuis (University of Illinois, Chicago, IL, USA) around the impact of the patient/care team relationship on health outcomes in asthma based on racial and socioeconomic differences. The abstract ‘Racial and Socioeconomic Differences in Perceived Quality of the Patient/Care Team Relationship Among Individuals with Asthma’ was presented at […]

We were delighted to talk with Dr. Juan Carlos Cardet (University of South Florida, Tampa, FL, USA) to discuss the PREPARE study, testing a Patient-Activated Reliever-Triggered Inhaled Corticosteroid (ICS) Strategy (PARTICS) in African American/Black and Hispanic/Latinx patients. The abstract ‘Successfully Reducing Severe Asthma Exacerbations and Improving Asthma Control in a Pragmatic Study in African American/Black […]

Talking abstract delivered by Dr Mark Arnold (Emory University School of Medicine, Atlanta, GA, USA) for the paper: Arnold M, Kuruvilla M and Levy JM. Management of Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease. touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):Online ahead of journal publication.